Exagen Inc. Form 8-K Summary
Business Context and Reporting Period
Exagen Inc. (XGN), a Delaware corporation, filed this Current Report on Form 8-K on November 17, 2023. The report details the entry into a material definitive agreement regarding the company's equity offering program.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a contractual amendment to an existing sales agreement.
Material Changes
On November 17, 2023, the Company entered into Amendment No. 1 to its Sales Agreement dated September 15, 2022, with Cowen and Company, LLC. The amendment modifies the Company's at-the-market (ATM) equity offering program to comply with General Instruction I.B.6 of Form S-3. Key terms include:
- Offering Limit: The Company may issue and sell common stock with an aggregate offering price of up to $50,000,000.
- Public Float Restriction: If the Company's public float remains below $75.0 million, it cannot sell ATM shares exceeding one-third of its public float in any twelve-month period.
- Recent Activity: The Company has not offered any securities pursuant to Instruction I.B.6 during the twelve-month period preceding this report.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks beyond the standard legal disclaimer that the report does not constitute an offer to sell securities. The primary contingency noted is the limitation on share sales based on the Company's public float valuation.
Investor Verification Checklist
- Verify the Company's current public float to determine if the one-third sales limitation under Instruction I.B.6 is currently active.
- Review the full text of Amendment No. 1 (Exhibit 1.1) for specific terms regarding termination or additional covenants.
- Check recent trading volumes and share counts to assess the potential dilution impact of the $50,000,000 ATM program.
- Confirm the Company's current status as an emerging growth company and any related reporting exemptions.